Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2018
|
Jan M Lundberg EVP,Science&Tech and Pres. LRL |
BUY
Exercise of conversion of derivative security
|
Direct |
36,252
+14.47%
|
-
|
|
Feb 01
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
9,533
-15.8%
|
$772,173
$81.45 P/Share
|
|
Feb 01
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+26.11%
|
-
|
|
Feb 01
2018
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
11,764
-8.96%
|
-
|
|
Feb 01
2018
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,559
-6.79%
|
$774,279
$81.45 P/Share
|
|
Feb 01
2018
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+13.15%
|
-
|
|
Feb 01
2018
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Payment of exercise price or tax liability
|
Direct |
7,133
-10.91%
|
$577,773
$81.45 P/Share
|
|
Feb 01
2018
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
BUY
Exercise of conversion of derivative security
|
Direct |
15,993
+19.66%
|
-
|
|
Feb 01
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Payment of exercise price or tax liability
|
Direct |
9,294
-6.11%
|
$752,814
$81.45 P/Share
|
|
Feb 01
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
BUY
Exercise of conversion of derivative security
|
Direct |
21,326
+12.3%
|
-
|
|
Jan 29
2018
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
4,279
+5.71%
|
$372,273
$87.6 P/Share
|
|
Jan 29
2018
|
Melissa S Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
BUY
Grant, award, or other acquisition
|
Direct |
3,759
+19.31%
|
$327,033
$87.6 P/Share
|
|
Jan 29
2018
|
Jan M Lundberg EVP,Science&Tech and Pres. LRL |
BUY
Grant, award, or other acquisition
|
Direct |
22,890
+11.39%
|
$1,991,430
$87.6 P/Share
|
|
Jan 29
2018
|
Enrique A Conterno SVP&Pres, LillyDiab & LillyUSA |
BUY
Grant, award, or other acquisition
|
Direct |
12,437
+8.94%
|
$1,082,019
$87.6 P/Share
|
|
Jan 29
2018
|
Stephen F Fry SVP, HR & Diversity |
BUY
Grant, award, or other acquisition
|
Direct |
9,937
+9.87%
|
$864,519
$87.6 P/Share
|
|
Jan 29
2018
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,407
+9.41%
|
$1,079,409
$87.6 P/Share
|
|
Jan 29
2018
|
Aarti S. Shah SVP & CIDO |
BUY
Grant, award, or other acquisition
|
Direct |
2,868
+15.44%
|
$249,516
$87.6 P/Share
|
|
Jan 29
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
BUY
Grant, award, or other acquisition
|
Indirect |
1,363
+8.4%
|
$118,581
$87.6 P/Share
|
|
Jan 29
2018
|
Susan Mahony SVP & Pres., Lilly Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
12,412
+19.44%
|
$1,079,844
$87.6 P/Share
|
|
Jan 29
2018
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
BUY
Grant, award, or other acquisition
|
Direct |
12,662
+8.83%
|
$1,101,594
$87.6 P/Share
|
|
Jan 29
2018
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
1,599
+9.04%
|
$139,113
$87.6 P/Share
|
|
Jan 29
2018
|
Joshua L Smiley |
BUY
Grant, award, or other acquisition
|
Direct |
7,202
+23.82%
|
$626,574
$87.6 P/Share
|
|
Jan 29
2018
|
Myles O'Neill SVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,491
+14.63%
|
$477,717
$87.6 P/Share
|
|
Jan 29
2018
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,933
+27.76%
|
$168,171
$87.6 P/Share
|
|
Jan 29
2018
|
Michael J Harrington Senior VP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,158
+17.12%
|
$1,405,746
$87.6 P/Share
|
|
Jan 29
2018
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
BUY
Grant, award, or other acquisition
|
Direct |
9,316
+15.88%
|
$810,492
$87.6 P/Share
|
|
Jan 15
2018
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
128
+0.32%
|
$10,880
$85.29 P/Share
|
|
Jan 15
2018
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
64
+0.11%
|
$5,440
$85.29 P/Share
|
|
Jan 15
2018
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
113
+2.04%
|
$9,605
$85.29 P/Share
|
|
Dec 18
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
127
+0.32%
|
$10,922
$86.08 P/Share
|
|
Dec 18
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
112
+2.06%
|
$9,632
$86.08 P/Share
|
|
Dec 13
2017
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
200,000
-0.08%
|
$17,600,000
$88.53 P/Share
|
|
Dec 11
2017
|
Jeffrey N Simmons SVP&Pres. Elanco Animal Health |
SELL
Open market or private sale
|
Direct |
12,500
-9.12%
|
$1,075,000
$86.46 P/Share
|
|
Dec 04
2017
|
Susan Mahony SVP & Pres., Lilly Oncology |
SELL
Open market or private sale
|
Direct |
36,585
-40.0%
|
$3,146,310
$86.18 P/Share
|
|
Dec 04
2017
|
Alfonso G Zulueta SVP & President, Lilly Int'l |
SELL
Open market or private sale
|
Direct |
3,532
-8.1%
|
$303,752
$86.0 P/Share
|
|
Dec 03
2017
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,601
-2.36%
|
$221,085
$85.32 P/Share
|
|
Dec 03
2017
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,496
+4.76%
|
-
|
|
Dec 03
2017
|
Stephen F Fry SVP, HR & Diversity |
SELL
Payment of exercise price or tax liability
|
Direct |
3,567
-4.12%
|
$303,195
$85.32 P/Share
|
|
Dec 03
2017
|
Stephen F Fry SVP, HR & Diversity |
BUY
Exercise of conversion of derivative security
|
Direct |
7,557
+8.03%
|
-
|
|
Dec 03
2017
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,070
-25.68%
|
$90,950
$85.32 P/Share
|
|
Dec 03
2017
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,281
+44.05%
|
-
|
|
Nov 20
2017
|
Ellen R Marram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+3.5%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Carolyn R Bertozzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,763
+50.0%
|
$146,329
$83.18 P/Share
|
|
Nov 20
2017
|
Michael L Eskew Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+4.97%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+3.64%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Franklyn G Prendergast Director |
BUY
Grant, award, or other acquisition
|
Direct |
802
+1.16%
|
$66,566
$83.18 P/Share
|
|
Nov 20
2017
|
Kathi P Seifert Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+2.74%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,055
+4.99%
|
$170,565
$83.18 P/Share
|
|
Nov 20
2017
|
Katherine Baicker Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,924
+11.42%
|
$159,692
$83.18 P/Share
|
|
Nov 20
2017
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+28.24%
|
$169,320
$83.18 P/Share
|